Journal article icon

Journal article

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

Abstract:

This phase II study determined the efficacy and safety of alemtuzumab, a humanized anti-CD52 monoclonal antibody, delivered subcutaneously as first-line therapy, over a prolonged treatment period of 18 weeks in 41 patients with symptomatic B-cell chronic lymphocytic leukemia (B-CLL). Injections were administered subcutaneously 3 times per week, from week 2 to 3 onward. An overall response rate (OR) of 87% (95% CI, 76%-98%; complete remission [CR], 19%; partial remission [PR], 68%) was achieve...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1182/blood-2002-01-0159

Authors


Journal:
Blood More from this journal
Volume:
100
Issue:
3
Pages:
768-773
Publication date:
2002-08-01
DOI:
EISSN:
1528-0020
ISSN:
0006-4971

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP